These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
32. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137 [TBL] [Abstract][Full Text] [Related]
33. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life. Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814 [TBL] [Abstract][Full Text] [Related]
34. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series. Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Radiation Segmentectomy with Sarwar A; Malik MS; Vo NH; Tsai LL; Tahir MM; Curry MP; Catana AM; Bullock AJ; Parker JA; Eckhoff DE; Nasser IA; Weinstein JL; Ahmed M Radiology; 2024 May; 311(2):e231386. PubMed ID: 38713023 [TBL] [Abstract][Full Text] [Related]
36. Impact of SPECT corrections on 3D-dosimetry for liver transarterial radioembolization using the patient relative calibration methodology. Pacilio M; Ferrari M; Chiesa C; Lorenzon L; Mira M; Botta F; Becci D; Torres LA; Coca Perez M; Vergara Gil A; Basile C; Ljungberg M; Pani R; Cremonesi M Med Phys; 2016 Jul; 43(7):4053. PubMed ID: 27370124 [TBL] [Abstract][Full Text] [Related]
37. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962 [TBL] [Abstract][Full Text] [Related]
38. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. Gnesin S; Canetti L; Adib S; Cherbuin N; Silva Monteiro M; Bize P; Denys A; Prior JO; Baechler S; Boubaker A J Nucl Med; 2016 Nov; 57(11):1672-1678. PubMed ID: 27307346 [TBL] [Abstract][Full Text] [Related]
39. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma. Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180 [TBL] [Abstract][Full Text] [Related]
40. Maximum tumor-absorbed dose measured by voxel-based multicompartmental dosimetry as a response predictor in yttrium-90 radiation segmentectomy for hepatocellular carcinoma. Orcajo Rincón J; Regi AR; Peña AM; Berenguer LR; Leyte MG; Martín LC; Atance García De La Santa J; Boyra ME; Ruiz CG; Rodríguez AC; Farto JCA EJNMMI Phys; 2023 Feb; 10(1):7. PubMed ID: 36745227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]